A61K 39/001111
Immunoglobulin superfamily
Official title: {Immunoglobulin superfamily}
A61K39/001111 (Immunoglobulin superfamily) appears on 219 US grants and 426 published applications in this corpus.
Search patents in A61K- Granted patents
- 219
- Published applications
- 426
- Assignees
- 174
- Inventors
- 682
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 3 |
| 2003 | 0 | 3 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 0 |
| 2008 | 0 | 2 |
| 2009 | 0 | 4 |
| 2010 | 1 | 2 |
| 2011 | 3 | 6 |
| 2012 | 2 | 0 |
| 2013 | 1 | 1 |
| 2014 | 2 | 3 |
| 2015 | 0 | 8 |
| 2016 | 4 | 9 |
| 2017 | 2 | 7 |
| 2018 | 7 | 21 |
| 2019 | 17 | 35 |
| 2020 | 37 | 68 |
| 2021 | 44 | 52 |
| 2022 | 18 | 50 |
| 2023 | 23 | 48 |
| 2024 | 23 | 43 |
| 2025 | 20 | 37 |
| 2026 | 14 | 20 |
By publication year. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- NKG2A-targeting antibody and use thereof6 Oct 2026US 12,753,231 B2Bioheng Therapeutics Limited
- Peptide tags for ligand induced degradation of fusion proteins15 Sep 2026US 12,735,463 B2Dana-Farber Cancer Institute, Inc.
- Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers4 Aug 2026US 12,698,512 B2City of Hope
- Ionizable lipids for nucleic acid delivery26 May 2026US 12,636,368 B2Global Life Sciences Solutions Canada ULC
- Oncolytic virus compositions and methods for the treatment of cancer26 May 2026US 12,637,510 B2City of Hope
- Immunoregulatory antigen-presenting vesicles24 Sep 2026US 2026/0284164 A1California Institute of Technology
- Methods and compositions for cancer treatment using recombinant polypeptides24 Sep 2026US 2026/0284226 A1Infinitopes Limited
- Ionizable lipids for nucleic acid delivery17 Sep 2026US 2026/0273066 A1Global Life Sciences Solutions Canada ULC
- Peptide linkers for modulating antigen immune response in cancer vaccines27 Aug 2026US 2026/0248899 A1Northwestern University
- Design method and production method for nucleic acid construct and protein complex20 Aug 2026US 2026/0240966 A1University of Tsukuba
Most cited
By later US patents
- Composition comprising a complexed (M)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof79US 9,572,874 B2CureVac AG · 2017
- Dock-and-lock (DNL) vaccines for cancer therapy68US 7,901,680 B2IBC Pharmaceuticals, Inc. · 2011
- Combination of the application of antibodies for immunostimulation together with glucocorticoids58US 8,709,421 B2Trion Pharma GmbH · 2014
- Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity42US 8,551,480 B2IBC Pharmaceuticals, Inc. · 2013
- Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen35US 10,010,592 B2CureVac AG · 2018